Drug Trial Radar · NCT05513703
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
9
Actual
Start
Nov 21, 2022
Primary completion
Oct 28, 2024
Study completion Oct 28, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine how telisotuzumab vedotin affects the disease state in adult participants with previously untreated participants with MET amplified non-squamous NSCLC. Change in disease activity will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of MET amplified non-squamous NSCLC. Participants receive intravenously (IV) infused of telisotuzumab vedotin. Approximately 70 adult participants with previously untreated MET amplified locally advanced/metastatic non-squamous NSCLC will be enrolled in the study in approximately 110 sites worldwide. Participants will receive IV telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Non Small Cell Lung Cancer
Interventions
Telisotuzumab VedotinBiological
Intravenous (IV) Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) as Assessed by an Independent Central Review (ICR)Time frame: Up to approximately 1.5 years
Locations
29 sites in 9 countries. Site status is shown where the registry gives one.
Cancer and Blood Speciality Clinic - Los Alamitos /ID# 251671
Los Alamitos, California
Valley Medical Center /ID# 251880
Renton, Washington
Monash Health - Monash Medical Centre /ID# 247679
Clayton, Victoria, Australia
Centre Jean Perrin /ID# 246268
Clermont-Ferrand, France
CHU Lille - Hôpital Albert Calmette /ID# 246263
Lille, Hauts-de-France, France
Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 246267
Bron, Rhone, France
Asklepios Fachkliniken Muenchen-Gauting /ID# 248082
Gauting, Germany
Rabin Medical Center /ID# 248631
Petah Tikva, Israel
Meir Medical Center /ID# 243208
Kfar Saba, Central District, Israel
Rambam Health Care Campus /ID# 246781
Haifa, H_efa, Israel
Hadassah Medical Center-Hebrew University /ID# 243298
Jerusalem, Jerusalem, Israel
The Chaim Sheba Medical Center /ID# 243207
Ramat Gan, Tel Aviv, Israel
IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 247585
Rome, Italy
Duplicate_Fondazione IRCCS San Gerardo dei Tintori /ID# 247584
Monza, Monza E Brianza, Italy
Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 248329
Candiolo, Torino, Italy
National Cancer Center Hospital East /ID# 250317
Kashiwa-shi, Chiba, Japan
Duplicate_National Hospital Organization Kyushu Cancer Center /ID# 250714
Fukuoka, Fukuoka, Japan
Hokkaido University Hospital /ID# 250316
Sapporo, Hokkaido, Japan
Osaka International Cancer Institute /ID# 251507
Osaka, Osaka, Japan
Shizuoka Cancer Center /ID# 251752
Sunto-gun, Shizuoka, Japan
National Cancer Center Hospital /ID# 250319
Chuo-ku, Tokyo, Japan
Keimyung University Dongsan Hospital /ID# 247371
Daegu, Gyeongsangbuk-do, South Korea
Pusan National University Yangsan Hospital /ID# 248489
Yangsan, Gyeongsangnam-do, South Korea
Chungbuk National University Hospital /ID# 248405
Cheongju-si, North Chungcheong, South Korea
Samsung Medical Center /ID# 248407
Seoul, Seoul Teugbyeolsi, South Korea
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 248144
Kaohsiung City, Taiwan
National Cheng Kung University Hospital /ID# 248142
Tainan, Taiwan
Linkou Chang Gung Memorial Hospital /ID# 248145
Taoyuan City, Taiwan
Kaohsiung Chang Gung Memorial Hospital /ID# 248143
Kaohsiung City, Kaohsiung, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.